Morgan Stanley Names NetEase Its Top Pick Ahead of Ananta’s 2027 Global Launch
The $163 price target sits about 35% above the latest close.
Already have an account? Sign in.
The $163 price target sits about 35% above the latest close.
Sangoma shareholders get $4.925 cash plus BRC stock, about $5.23 a share—a 47% premium.
Summit and AstraZeneca will co-develop ivonescimab combinations, starting with GI cancers. Each company keeps rights to its own medicines.
The U.S. Army selected Navitas to develop 10 kV silicon carbide chips under the ALATTIS program for defense and critical infrastructure use.